EN
SINOVAC Receives Visits from Bogotá Mayor and Colombian Ambassador to China in Beijing
On December 5, 2023, Mayor of Bogotá Claudia López and Colombian Ambassador to China Sergio Caffaratti, visited Sinovac Biotech Ltd. ("SINOVAC" or the "Company") in Beijing to meet with Mr. Weidong Yin, Chairman, President, and CEO of SINOVAC.
The visit follows SINOVAC’s designation as the exclusive strategic partner of BogotáBio, the first local human vaccine company with full cycle of production capability to be established in Colombia’s capital city of Bogota. The partnership aims to develop a range of vaccines that effectively address Colombia’s urgent need for immunization against various infectious diseases.
Mayor López expressed high expectations for the project, believing that through this initiative, Colombia will acquire the capability to produce human vaccines with different technologies, which will better address future public health challenges.
Mr. Yin noted that the BogotáBio project not only benefits Colombia but also will contribute to disease prevention and control across the Latin American region. SINOVAC has established a robust vaccine localization plan for Colombian after the outbreak of the COVID-19 pandemic and both sides Bogota government and Sinovac aim to expand the partnership to effectively meet the unmet medical needs in the country.
Ambassador Caffaratti emphasized that the project of BogotáBio serves as a model for cooperation between China and Colombia, and the two countries are committed to continuing and deepening collaboration across many sectors.
The Colombian delegation also included Ruth Amparo Medina, Director of International Relations for the City of Bogota, Oscar Felipe Rueda, Commercial Counselor at the Colombian Embassy in China, and Daniel Mesa, First Secretary at the Embassy. SINOVAC’s Chief Business Officer Ms. Helen Yang and Chief Operating Officer Mr. Qiang Gao also accompanied the delegation.
Colombia is one of the first countries in the world to adopt SINOVAC's COVID-19 vaccine, CoronaVac®, granting it emergency use approval in June 2021. To date, CoronaVac® and Healive®, SINOVAC’s hepatitis A vaccine, have been successfully distributed nationwide, effectively bridging the local vaccination gap with safe and affordable products.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.